Recent News Releases

CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022 Melbourne, Australia: CSL is committed to the manufacture of approximately 50 million doses of the AstraZeneca COVID-19...

Summit, NJ, USA 14 Oct 2021 Seqirus, a global leader in influenza prevention, and a business of CSL Limited (ASX:CSL), today announced that The New England Journal of Medicine has published...

• Expert modelling points to a more severe influenza season than in previous years.1 • The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Executive committee members Lee Heeson and Gregory Oakes to leave the company for personal reasons Succession planning ongoing St. Gallen, Switzerland,...

CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors Melbourne, Australia: CSL has confirmed all Australian on-site employees, contractors and visitors will be required to be...

CSL introduced a scholarship program for U.S. employees and their dependents as part of delivering on its promise to diversity, equity and inclusion. 05 Oct 2021 Global biotech leader CSL has...

• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives • Company will utilize its combination of...

First orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan Partner Kissei to market TAVNEOS® in Japan, with launch expected as soon as...

CSL has remained agile to stay ahead of the pandemic challenges and has redirected resources to where it can add the most value to address the pandemic challenges. From the time the coronavirus...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Sparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis...

CSL confirms there was a positive COVID-19 case at its Broadmeadows manufacturing facility last week. All employees and contractors who were present at the same time as the confirmed case have...

Global biotech leader CSL and the Urban League of Philadelphia are working to address some of the most pressing needs in the community, including efforts to strengthen Public Health, Leadership...

2021 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) includes new recommendations on management of iron deficiency with Ferinject® (ferric carboxymaltose)...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing...

• Appoints Roberta Duncan as new program lead to drive technology advancement • Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza Summit, NJ, USA 19 Aug...

The updated guideline empowers physicians with the confidence to expand the treatment options prescribed for CIDP patients 09 Aug 2021 KING OF PRUSSIA, Pa. – Aug. 9, 2021 – Global...

AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Net sales up 5.0% and EBITDA up 5.3% at constant exchange rates (CER), as patient access recovered in line with easing COVID-19 restrictions in key...

KING OF PRUSSIA, PA 03 Aug 2021 CSL Behring, a global biotherapeutics leader received U.S. Food and Drug Administration (FDA) approval for its supplemental request (submitted Aug. 30, 2020) for...

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic. Summit, NJ, USA 27 Jul 2021 Seqirus offers a...

COVID-19 pandemic significantly impacted the DIAMOND study, leading to lower-than-anticipated enrolment and slower incidence of cardio-vascular events Independent study Executive Committee...

Abbas Hussain will take over as CEO of the Vifor Pharma Group on 16 August 2021 Succeeding Stefan Schulze, who has decided to step down and leave the company for personal reasons St. Gallen,...

KING OF PRUSSIA, Pa. 08 Jun 2021 Global biotherapeutics leader CSL Behring today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Hizentra for coverage under Medicare...

Safeguarding our people, patients and donors remains our top priority. As the COVID-19 pandemic evolves, CSL continues to provide medicines to patients around the world. We’re also exploring new...

$2.5 Million Funding Available to Australian Biomedical Researchers Melbourne, Australia: 01.06.2021: Australia’s top biomedical researchers are invited to apply for one of two CSL Centenary...

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool. Liverpool, UK 01 Jun 2021 Seqirus Liverpool is the...